In the future, investigators should consider evaluating if heart rate, tumor volume, surrogate markers of tumor hypoxia, IL-10 production, NK-like cell function and circulating lymphocyte count could be useful markers for patient selection or stratification of patients in clinical trials evaluating CNV-NT for the treatment of cancer. This evidence concerns the gene IL10 and neoplasm.